Drug Profile
Labafenogene marselecobac - Synlogic
Alternative Names: SYNB-1934Latest Information Update: 23 Apr 2024
Price :
$50
*
At a glance
- Originator Ginkgo Bioworks; Synlogic
- Developer Synlogic
- Class Bacteria; Probiotics
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Phenylketonuria
Most Recent Events
- 23 Apr 2024 Discontinued - Phase-III for Phenylketonuria in USA (PO), prior to April 2024
- 08 Feb 2024 Labafenogene marselecobac - Synlogic is available for licensing as of 08 Feb 2024. https://www.synlogictx.com/collaborations-before-after/
- 08 Feb 2024 Synlogic terminates the phase-III Synpheny-3 trial in Phenylketonuria in USA, Canada, Georgia and Turkey,based on an internal review of interim results of the trial , (NCT05764239),